4 October 2022
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Change of Auditor
Proteome Sciences Plc ("Proteome Sciences", or "the Company") announces that the Board has approved the appointment of Cooper Parry Group Limited (Cooper Parry) as the Group's new external auditor, and that BDO LLP ("BDO") has resigned as the Group's auditor.
Cooper Parry will conduct the audit of the Group's financial statements for the financial period to 31 December 2022 and a proposal to re-appoint Cooper Parry as auditors of the Group will be subject to the approval of shareholders at the 2023 Annual General Meeting.
BDO has been the auditor for the Company since 2014 and we thank them for their services over this time. BDO has confirmed to the Company that there are no matters connected with their ceasing to hold office that need to be brought to the attention of the members or creditors of the Company for the purposes of section 519 of the Companies Act 2006.
- Ends -
For further information:
| Proteome Sciences plc
| |
| Dr Mariola Soehngen, Chief Executive Officer Abdelghani Omari, Chief Financial Officer Dr Ian Pike, Chief Scientific Officer Richard Dennis, Chief Commercial Officer | Tel: +44 (0)20 7043 2116 |
| Allenby Capital Limited (AIM Nominated Adviser & Broker) | |
| John Depasquale/ Jeremy Porter Tel: +44 (0)20 3328 5656 | |
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
The Company has its headquarters in Cobham, UK, with laboratory facilities in Frankfurt, Germany.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.